Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):331–335. doi: 10.1111/j.1365-2125.1984.tb02472.x

Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.

M J Kendall, D B Jack, S J Laugher, J Lobo, S Rolf Smith
PMCID: PMC1463644  PMID: 6487472

Abstract

Nifedipine, metoprolol and atenolol were administered orally to young, healthy volunteers. Each drug was given alone and nifedipine was also given with both beta-adrenoceptor blockers. Each drug was given for 3 days immediately before the study days. Plasma and urine drug concentrations were measured and the relevant pharmacokinetic parameters calculated. No pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers was revealed.

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki K., Kondo S., Mochizuki A., Yoshida T., Kato S., Kato K., Takikawa K. Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade. Am Heart J. 1978 Aug;96(2):218–226. doi: 10.1016/0002-8703(78)90089-3. [DOI] [PubMed] [Google Scholar]
  2. Bassan M., Weiler-Ravell D., Shalev O. Additive antianginal effect of verapamil in patients receiving propranolol. Br Med J (Clin Res Ed) 1982 Apr 10;284(6322):1067–1070. doi: 10.1136/bmj.284.6322.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dargie H. J., Lynch P. G., Krikler D. M., Harris L., Krikler S. Nifedipine and propranolol: a beneficial drug interaction. Am J Med. 1981 Oct;71(4):676–682. doi: 10.1016/0002-9343(81)90238-2. [DOI] [PubMed] [Google Scholar]
  4. Dean S., Kendall M. J. Nifedipine in the treatment of difficult hypertensives. Eur J Clin Pharmacol. 1983;24(1):1–5. doi: 10.1007/BF00613919. [DOI] [PubMed] [Google Scholar]
  5. Eggertsen R., Hansson L. Effects of treatment with nifedipine and metoprolol in essential hypertension. Eur J Clin Pharmacol. 1982;21(5):389–390. doi: 10.1007/BF00542324. [DOI] [PubMed] [Google Scholar]
  6. Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487–493. doi: 10.1002/cpt1973144part1487. [DOI] [PubMed] [Google Scholar]
  7. Jack D. B., Kendall M. J., Dean S., Laugher S. J., Zaman R., Tenneson M. E. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos. 1982 Jan-Mar;3(1):47–54. doi: 10.1002/bdd.2510030107. [DOI] [PubMed] [Google Scholar]
  8. Jack D. B., Wilkins M., Quarterman C. P. Lack of evidence for polymorphism in metoprolol metabolism. Br J Clin Pharmacol. 1983 Aug;16(2):188–190. doi: 10.1111/j.1365-2125.1983.tb04984.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kendall M. J., John V. A., Quarterman C. P., Welling P. G. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol. Eur J Clin Pharmacol. 1980 Feb;17(2):87–92. doi: 10.1007/BF00562615. [DOI] [PubMed] [Google Scholar]
  10. Kondo S., Kuchiki A., Yamamoto K., Akimoto K., Takahashi K., Awata N., Sugimoto I. Identification of nifedipine metabolites and their determination by gas chromatography. Chem Pharm Bull (Tokyo) 1980 Jan;28(1):1–7. doi: 10.1248/cpb.28.1. [DOI] [PubMed] [Google Scholar]
  11. McLean A. J., Skews H., Bobik A., Dudley F. J. Interaction between oral propranolol and hydralazine. Clin Pharmacol Ther. 1980 Jun;27(6):726–732. doi: 10.1038/clpt.1980.103. [DOI] [PubMed] [Google Scholar]
  12. Mcainsh J., Simpson W. T., Holmes B. F., Young J., Ellis S. H. Bioavailability of atenolol formulations. Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323–332. doi: 10.1002/bdd.2510010604. [DOI] [PubMed] [Google Scholar]
  13. Ochs H. R., Carstens G., Greenblatt D. J. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med. 1980 Aug 14;303(7):373–377. doi: 10.1056/NEJM198008143030705. [DOI] [PubMed] [Google Scholar]
  14. Peet M., Middlemiss D. N., Yates R. A. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet. 1980 Nov 1;2(8201):978–978. doi: 10.1016/s0140-6736(80)92135-2. [DOI] [PubMed] [Google Scholar]
  15. Regårdh C. G., Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980 Nov-Dec;5(6):557–569. doi: 10.2165/00003088-198005060-00004. [DOI] [PubMed] [Google Scholar]
  16. Scales B., Copsey P. B. The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol. 1975 Jun;27(6):430–433. doi: 10.1111/j.2042-7158.1975.tb09473.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES